FDA Orange Book · active-ingredient family
Trifarotene
Trifarotene is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:AKLIEF · NDA 211527
1
Brand (NDA)
0
Generics (ANDA)
3
Listed patents
0
Exclusivity periods
Brand (NDA) products · cream
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| AKLIEFRLD | GALDERMA LABS LP | NDA 211527 | — | Oct 04, 2019 |
Listed patents (3)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7807708 | Jul 19, 2031 | in 5 yr 2 mo | SubstanceProduct |
| 9084778 | May 30, 2033 | in 7 yr 1 mo | ProductU-134 |
| 9498465 | May 30, 2033 | in 7 yr 1 mo | ProductU-1033 |
Trifarotene — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
